source
- Roche partners with Chinese biotech Defand Therapeutics to co-develop new medicinesRoche announced a partnership with Chinese biotech startup Defand Therapeutics aimed at joint discovery of new drug candidates. Unlike the typical licensing deals where companies obtain rights to…
- Argenx's Vyvgart fails to beat placebo in Phase 3 Sjögren's disease trialArgenx announced that its marketed antibody therapy Vyvgart did not show superiority over placebo in a Phase 3 study involving patients with Sjögren's disease, a chronic autoimmune condition. The…